pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 36 Non-oncology: 23
Oncology: 13
Under Consideration for Negotiation 33 Non-oncology: 18
Oncology: 15
Completed Negotiations 445 With Letter of Intent: 384
Without agreement: 61
Negotiations That Were Not Pursued 84

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Duobrii Bausch Health, Canada Inc. Psoriasis, moderate to severe plaque
Ilumya Sun Pharma Canada Inc. Psoriasis, moderate to severe plaque
Tafinlar/Mekinist Novartis Pharmaceuticals Canada Inc. Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease
Kynmobi Sunovion Pharmaceuticals Canada Inc. Parkinson's Disease
Kesimpta Novartis Pharma Canada Inc. Relapsing-Remitting Multiple Sclerosis
Evrysdi HOFFMANN-LA ROCHE LIMITED  Spinal Muscular Atrophy
Entresto Novartis Pharmaceuticals Canada Inc. Heart failure, NYHA class II or III

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Trikafta Vertex Pharmaceuticals (Canada) Incorporated Cystic Fibrosis, F508del CFTR mutation
Osnuvo AVIR Pharma Inc. osteoporosis
Crysvita Ultragenyx Canada Inc. X-Linked Hypophosphatemia
Vocabria and Cabenuva VIIV HEALTHCARE ULC HIV Infection
Beovu Novartis Pharma Canada Inc. Age-Related Macular Degeneration
Cabometyx Ipsen Biopharmaceuticals For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Botox Allergan Inc. migraine, chronic

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks